Dr Prasher, Assistant Professor, Department of Chemistry, University of Petroleum & Energy Studies, has research experience of 8 years in medicinal chemistry and biomaterials, while working in the field of anti-inflammatory and anticancer chemotherapy. The research team led by Dr. Prasher focuses on the development of rationally designed molecules for targeting various disorders, including inflammation, cancer, and antimicrobial MDR, which also includes the Identification of novel pharmacophores, chemical moieties and APIs for developing the potential chemotherapeutics. With inspiring national/ international collaborations, Dr. Prasher has published more than 45 peer reviewed publications, and >10 book chapters in the journals of repute. Dr. Prasher serves as reviewer for reputed journals published by Elsevier, ACS, RSC and Springer publishers, with the status “Recognized reviewer. Dr. Prasher has been a recipient of the prestigious Junior/ Senior Research Fellowship by the Council of Scientific and Industrial Research, Government of India (2012-2015). Dr. Prasher received ‘Lectureship’ award by the Government of India (2012). Dr Mousmee Sharma, Assistant Professor, Department of Chemistry, Uttaranchal University, has research experience of more than 5 years in Physical Chemistry and Biomaterials, while working in the field of bio membranes. The recent research work of Dr Mousmee is focused on the development of mucoadhesive materials for drug delivery across the physiological mucus barrier. Dr Mousmee has published 50 research/ review articles and 20 book chapters in the journals of high repute. A ‘Gold Medalist’ in her post-graduation, Dr Mousmee recently received “Recognized reviewer status by Elsevier and ‘Brand Ambassador’ for the ‘Bentham Science Publishers’ for the year 2021.Dr. Raimar Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany and PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt. He joined the University of Alberta in 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015. He is member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.Dr. Neal M. Davies is a distinguished professor and former Dean of the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, Canada. With over 20 years of experience, his research focuses on drug mechanisms, disposition, toxicity, and novel delivery systems, especially in anti-inflammatory drugs and natural products. He has authored more than 300 peer-reviewed publications, five books, and numerous patents, with over 18,000 citations highlighting his impactful contributions. Committed to education, Dr. Davies trains future pharmacists and researchers while fostering interdisciplinary collaborations globally. His expertise spans regulatory affairs, clinical trials, and translational medicine, making him a sought-after consultant and speaker. Under his leadership, his faculty has maintained top international rankings, reflecting his dedication to advancing pharmaceutical sciences. His work continues to shape innovative approaches in drug development and delivery, positioning him as a leading figure in the field.In 2012, Prof. Zacconi became Assistant Professor in the Faculty of Chemistry at Pontificia Universidad Católica de Chile (Chile). Currently, her Associate Professor position is shared between the Faculty of Chemistry and Pharmacy and the Institute for Biological and Medical Engineering (IIBM). Moreover, Dr. Zacconi has a research experience of more than 11 years in organic chemistry, medicinal chemistry and biomaterials, while working in the field of chemical synthesis, structural analyses, drug design, and materials. Dr. Zacconi’s research focuses on the intersections of organic chemistry, medicinal chemistry, engineering and biological chemistry, developing multi- and interdisciplinary research to understand the complexity in the design, synthesis and biological evaluation of bioactive compounds. Besides, Prof. Zacconi is an Associate Researcher at the Research Center for Nanotechnology and Advanced Materials (CIEN-UC). Additionally, Dr. Zacconi acts as a reviewer for international journals and she has published research papers, book chapters, books and reviews. Kamal Dua is a Professor in the NICM Health Research Institute and the School of Science at Western Sydney University (WSU). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2026, 2025 and 2024 in Research Magazine by “The Australian in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2026, 2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.